FGEN vs. MCRB, OCS, KRRO, CRBP, LRMR, ANNX, NGNE, VERV, ERAS, and TBPH
Should you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Seres Therapeutics (MCRB), Oculis (OCS), Korro Bio (KRRO), Corbus Pharmaceuticals (CRBP), Larimar Therapeutics (LRMR), Annexon (ANNX), Neurogene (NGNE), Verve Therapeutics (VERV), Erasca (ERAS), and Theravance Biopharma (TBPH). These companies are all part of the "pharmaceutical preparations" industry.
FibroGen (NASDAQ:FGEN) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, community ranking, earnings, profitability and media sentiment.
FibroGen has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.
72.7% of FibroGen shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 2.0% of FibroGen shares are held by insiders. Comparatively, 5.1% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
FibroGen presently has a consensus price target of $2.00, indicating a potential upside of 66.67%. Seres Therapeutics has a consensus price target of $5.00, indicating a potential upside of 400.00%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than FibroGen.
Seres Therapeutics has a net margin of 0.00% compared to FibroGen's net margin of -143.57%.
In the previous week, FibroGen had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 4 mentions for FibroGen and 2 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.83 beat FibroGen's score of 0.22 indicating that Seres Therapeutics is being referred to more favorably in the news media.
Seres Therapeutics has lower revenue, but higher earnings than FibroGen. Seres Therapeutics is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks.
Seres Therapeutics received 181 more outperform votes than FibroGen when rated by MarketBeat users. Likewise, 72.48% of users gave Seres Therapeutics an outperform vote while only 62.36% of users gave FibroGen an outperform vote.
Summary
Seres Therapeutics beats FibroGen on 13 of the 17 factors compared between the two stocks.
Get FibroGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroGen Competitors List
Related Companies and Tools
